Nafamostat mesilate for anticoagulation in pediatric trauma patients undergoing extracorporeal membrane oxygenation: a two-center observational study in Northwest China - Summary - MDSpire

Nafamostat mesilate for anticoagulation in pediatric trauma patients undergoing extracorporeal membrane oxygenation: a two-center observational study in Northwest China

  • By

  • Weikai Wang

  • Zhe Lv

  • Haitong Wu

  • Hua Zhang

  • Zhen Chen

  • Yong Zhou

  • Zhangyan Guo

  • Jingmei Li

  • Le Ma

  • Dan Yao

  • Ying Wang

  • Ru Lin

  • Yajun Niu

  • Yuhao Ma

  • Xinxin Yan

  • Shan Jia

  • Taining Zhang

  • Yufei Wang

  • Yanqiang Du

  • Yi Wang

  • July 14, 2026

Share

Objective:

To evaluate the comparative efficacy of regional anticoagulation using nafamostat mesilate vs. systemic anticoagulation with unfractionated heparin in pediatric patients with trauma undergoing ECMO support.

Approach:
  • Outcome Measures: Clinical outcomes evaluated included transfusion requirements, use of coagulation-related agents, incidence of complications, and successful removal.
Key Findings:
  • No significant differences in blood cell classification and coagulation parameters at admission between groups.
  • The UFH group had a higher rate of new-onset active bleeding and circuit thrombosis compared to the nafamostat mesilate group (P < 0.05).
  • Mandatory anticoagulant discontinuation was significantly higher in the UFH group due to increased active bleeding.
Interpretation:

Limitations:
  • Small sample size of 40 patients.
  • Single-center and multi-center data may vary in generalizability.
Conclusion:

Original Source(s)

Related Content